Alimera Sciences, Inc. Overview
Pro stress-test →Alimera Sciences is a specialized pharmaceutical company focused on developing and commercializing prescription ophthalmic treatments for retinal diseases. The company leverages advanced sustained-release technology platforms, particularly its CONTINUOUS MICRODOSING technology, to deliver innovative solutions to patients with conditions including diabetic macular edema and non-infectious uveitis.
Strategic Profile
Pro stress-test →Alimera competes in the specialized ophthalmology market by addressing unmet clinical needs in retinal disease treatment where current therapies are inadequate. The company's proprietary drug delivery systems reduce injection frequency and improve patient outcomes, positioning it as a differentiated player in the ophthalmology sector. Following the merger agreement announced in June 2024, Alimera is now part of ANI Pharmaceuticals' rare disease portfolio.
Competitive Landscape
Pro stress-test →Alimera competes in specialty ophthalmology against larger pharmaceutical companies and biotech firms focused on retinal disease treatment. Key competitors include companies developing injectable and implant therapies for diabetic macular edema and uveitis, though Alimera's sustained-release delivery platform provides differentiation. The company operates in a fragmented market where clinical efficacy, patient convenience, and physician relationships drive competitive positioning.
Industry Context
Alimera Sciences, Inc. operates in Specialty Pharmaceutical (Ophthalmology).
Key facts
Founded: 2003 · Headquarters: Alpharetta, US · Employees: N/A · Revenue: N/A · Market cap: N/A